This week, Onduo released a whitepaper on the use of continuous glucose monitoring systems (CGMs) for type 2 diabetes care as part of a whole person health approach that supports people between visits with their primary care providers (PCPs). In the paper, Onduo spotlights its proactive virtual care model and tiered intervention capability to match people with the most appropriate care pathways. According to the company’s most recently published clinical results, a virtual care model that integrates the use of CGMs for people with the highest risk can help them achieve meaningful clinical outcomes. The company’s latest publication of its first prospective, single-arm trial in the Journal of Medical Internet Research (JMIR)1 adds to the growing evidence supporting CGM use in the Onduo virtual care model.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005348/en/
Onduo’s virtual care model integrates the use of CGMs for people with the highest risk to help them achieve meaningful clinical outcomes (Graphic: Business Wire)
“Onduo focuses on what happens at home to provide guideposts and direction. We use a digital footprint – including sensing devices like CGMs – to help us identify a series of interventions to provide the right care at the right time”, said Vindell Washington, MD, CEO at Onduo. “The real novelty of this approach is our ability to deliver a more extensive and rounded experience based on an individuals’ daily health habits and behaviors.”
How CGMs Improve Outcomes
Onduo expands on positive results from CGM usage in its recent prospective study in a newly published peer reviewed article in the JMIR. Results from Onduo’s single-arm trial demonstrated that program participants with suboptimal glycemic control at baseline had improved HbA1c and time in target (the percentage of time that they spent in the ideal glucose range of 70 to 180 mg/dL), decreased time in hyperglycemia, and had significant decreases in weight, systolic blood pressure and serum lipids after 4 months.
While access to CGMs has been limited for people with type 2 diabetes, there is growing recognition of the value of the use of this technology in managing glucose levels in this population2. Onduo’s data demonstrates how CGMs enable more precise diabetes management with continuous data from automatic readings, every five minutes throughout the day, revealing insights to trends over time. By including CGMs in its novel care model, Onduo helps members leverage telemedicine and access highest quality, proactive diabetes care based on their individual needs. In the whitepaper, Onduo describes how the intermittent use of CGMs provide rich information on an individual’s time in range and how to make adjustments to spend more time-in-range.
Recently, new data presented at the American Diabetes Association’s 80th Scientific highlights meaningfully lowered HbA1C in people with type 2 diabetes participating in the Onduo program, with significantly greater reductions in those using CGMs. The use of CGM in the highest risk group (baseline HbA1C over 9.0%) resulted in the greatest average HbA1C drop (-3.3%).3
Onduo’s endocrinologists are licensed to provide care and prescribe in 49 states and Washington, D.C., and the organization can fulfill durable medical equipment orders, allowing shipment of CGMs directly to members. Delivering CGM devices, incorporating insights from intermittent CGM use, and evaluating glycemic outcomes using CGM data are unique aspects of Onduo’s care model.
A New Era of Glucose Monitoring
Following the ADA’s Scientific Sessions, Onduo hosted a webinar about the future of care and improvement in outcomes for people living with type 2 diabetes. Thought leaders — including ADA’s CEO Tracey Brown, Dr. Richard Bergenstal of the International Diabetes Center, and Dexcom’s Dr. David Price — reflected on the needs of the population and how proactive virtual care and CGMs should be part of new standards of care.
“CGMs are amazing – and the real star of the show is what comes out of it – ‘time in range,’” said Richard Bergenstal, MD, Executive Director of the International Diabetes Center at Park Nicollet. “You can rely on this data as a good correlate for long term complications.”
We at Onduo are dedicated to making “healthy” easier, more accessible and finally personalized with our science-backed, data-driven virtual care model – one that can serve people living with chronic conditions and the organizations supporting them. Launched initially with the type 2 diabetes population and enabled by technology built by Verily Life Sciences, we deliver lifestyle and clinical interventions that leverage deep analytics, connected smart devices, best-in-class software, and access to specialty care. Onduo headquarters are based out of Newton, MA.
Majithia A, Kusiak CM, Armento Lee A et al. Improved Glycemic Outcomes in Adults with Type 2 Diabetes Participating in Continuous Glucose Monitor Driven Virtual Diabetes Clinic: A Prospective Trial. J Med Internet Res 2020;22(8):e21778 doi:10.2196/21778
American Diabetes Association. Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1)
Layne JE, Zisser H, Bergenstal RM et al. Change in A1c With and Without Intermittent Use of CGM In Adults With Type 2 Diabetes Participating in the Onduo Virtual Diabetes Clinic. Diabetes 2020 Jun; 69 (Supplement 1). doi.org/10.2337/db20-70-OR